Side-by-side · Research reference

IGF-1 LR3vsOvagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED10/58 cited

BTheoreticalHUMAN-REVIEWED2/42 cited

IGF-1 LR3

IGF-1 Analogue · Research

3–10×Potency vs IGF-I

Low IGFBPBinding affinity

ResearchStatus

Research only · SQ typical in animal models

Ovagen

Khavinson Bioregulator · Ovarian

OvarianTarget tissue

Di/Tri-peptidePeptide length

AnimalEvidence tier

Oral / SQ · Protocol varies

01Mechanism of Action

Parameter

IGF-1 LR3

Ovagen

Primary target

IGF-1 receptor (IGF-1R)McTavish 2009

Ovarian tissue chromatin complexes

Pathway

IGF-1R → IRS-1 → PI3K/Akt → Cell proliferation, protein synthesis, anti-apoptosisMuhlbradt 2009

Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation

Downstream effect

Enhanced cell proliferation, muscle anabolism, inhibition of apoptosis, increased telomerase activity

Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration

Feedback intact?

No — exogenous IGF analogue bypasses GH-mediated regulation

Presumed physiological — Khavinson peptides described as regulatory, not replacement

Origin

Synthetic 83-AA analogue: 13-AA N-terminal extension + Arg substitution at position 3

Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)

Antibody development

—

02Dosage Protocols

Parameter

IGF-1 LR3

Ovagen

Research dose (animal models)

Variable by protocol and species

In vivo murine atherosclerosis studies used sustained delivery.

—

In vitro typical concentration

10–1000 ng/mLThomas 2007

Dose-dependent effects on follicle growth and estradiol production.

—

Half-maximal stimulation

0.6 nM LR3 vs 1.5 nM native IGF-1Price 2004

2.5-fold greater potency in lung fibroblast proliferation.

—

Evidence basis

Animal / in vitro only

Theoretical / Russian-tradition

Human use

Not FDA-approved; no published human trials

—

Standard dose

—

10–20 mg / day (oral) or 1–2 mg SQ

Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.

Frequency

—

Once daily or cyclical (10–20 days per month)

Cyclical protocols common in Khavinson bioregulator tradition.

Duration

—

4–12 weeks per cycle

Khavinson protocols typically 1–3 months; repeat cycles as needed.

Route

—

Oral (capsule) or subcutaneous

Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.

03Metabolic / Fat Loss Evidence

Parameter

IGF-1 LR3

Ovagen

Mechanism

IGF-1R activation → lipolytic signaling; secondary to anabolic effects

—

Direct lipolytic evidence

Minimal — primarily anabolic/anti-apoptotic in literature

—

Atherosclerotic plaque effects

Reduced stenosis and core size in ApoE-KO micevon 2011

Plaque stabilization via vSMC phenotype modulation, not direct fat loss.

—

Human data

None published

—

04Side Effects & Safety

Parameter

IGF-1 LR3

Ovagen

Hypoglycemia risk

Theoretical — IGF-1 analogues can lower blood glucose

—

Excessive cell proliferation

Mitogenic signaling; theoretical tumor promotion risk

—

Telomerase activation

2–10-fold increase in prostate cancer cells (PC-3, DU-145, LAPC-4)Wetterau 2003

Critically involved in cancer cell immortalization.

—

Oocyte degeneration

Increased oocyte degeneration at high doses (≥1000 ng/mL) in bovine folliclesThomas 2007

—

Unregulated anabolism

Bypasses physiological GH/IGF-1 feedback; no pulsatility control

—

Unknown human safety profile

No published human trials; safety data absent

—

Reported adverse events

—

None documented in indexed literature

Theoretical hormonal effects

—

Ovarian stimulation — monitor for estrogen-sensitive conditions

Injection site reaction

—

Possible mild erythema (SQ route)

Long-term safety

—

Unknown — no PubMed-indexed RCTs

Absolute Contraindications

IGF-1 LR3

·Active malignancy or history of cancer
·Not approved for human use

Ovagen

·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
·Pregnancy

Relative Contraindications

IGF-1 LR3

·Diabetes or glucose intolerance
·Family history of cancer

Ovagen

·History of estrogen-sensitive tumors (monitor)
·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
·Endometriosis or fibroids (estrogen-responsive conditions)

05Administration Protocol

Parameter

IGF-1 LR3

Ovagen

1. Research use only

IGF-1 LR3 is not FDA-approved for human use. All administration data derives from animal or in vitro studies.

Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.

2. Typical research route

Subcutaneous or intraperitoneal injection in animal models. In vitro: added directly to culture medium at concentrations of 10–1000 ng/mL.Thomas 2007

1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.

3. Reconstitution (research)

Lyophilised powder reconstituted in sterile water or buffered saline per manufacturer protocol. Store at 2–8 °C after reconstitution.

Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.

4. Stability

Enhanced stability vs native IGF-1 due to reduced IGFBP binding; exact half-life in vivo not fully characterized in humans.

Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.

06Stack Synergy

IGF-1 LR3

+ GHRP-6

Multi-pathway

View GHRP-6 →

GHRP-6 stimulates endogenous GH release, which drives hepatic IGF-1 synthesis. IGF-1 LR3 provides exogenous, IGFBP-resistant IGF signaling. Combining upstream GH stimulation with downstream IGF receptor activation creates a dual-pathway anabolic effect. However, this bypasses natural feedback and carries compounded mitogenic risk.

GHRP-6: 100–200 mcg SQ · 2–3× daily
IGF-1 LR3: Research doses variable · post-workout typical in animal models
Note: Research context only — no human protocols exist
Primary benefit: Theoretical maximal anabolic signaling (GH + IGF axes)

+ Ipamorelin

Multi-pathway

View Ipamorelin →

Ipamorelin (selective GHRP) stimulates pulsatile GH release without cortisol/prolactin elevation. IGF-1 LR3 directly activates IGF-1R independent of GH. This stack targets both upstream (GH secretion) and downstream (IGF receptor) nodes but eliminates physiological feedback, raising safety concerns around unchecked proliferation.

Ipamorelin: 200–300 mcg SQ · evening
IGF-1 LR3: Research doses only · timing variable
Caution: No human data; animal/in vitro only
Primary benefit: Dual-axis anabolic signaling (theoretical)

Ovagen

— no documented stacks